-
1
-
-
0034567805
-
Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature
-
Von Wowern N. Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000, 90:765-772.
-
(2000)
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
, vol.90
, pp. 765-772
-
-
Von Wowern, N.1
-
4
-
-
67650251439
-
Diagnosis and treatment of familial cherubism characterized by early onset and rapid development
-
Mortellaro C., Bello L., Lucchina A.G., Pucci A. Diagnosis and treatment of familial cherubism characterized by early onset and rapid development. J Craniofac Surg 2009, 20:116-120.
-
(2009)
J Craniofac Surg
, vol.20
, pp. 116-120
-
-
Mortellaro, C.1
Bello, L.2
Lucchina, A.G.3
Pucci, A.4
-
5
-
-
33344477759
-
-
WHO, IARC Press, Lyon
-
Barnes L., Eveson J.W., Reichardt P., Sidrasky D. Pathology & genetics, head and neck tumours 2005, WHO, IARC Press, Lyon.
-
(2005)
Pathology & genetics, head and neck tumours
-
-
Barnes, L.1
Eveson, J.W.2
Reichardt, P.3
Sidrasky, D.4
-
6
-
-
0033362150
-
The gene for cherubism maps to chromosome 4p16.3
-
Mangion J., Rahman N., Edkins S., Barfoot R., Nguyen T., Sigurdsson A., et al. The gene for cherubism maps to chromosome 4p16.3. Am J Hum Genet 1999, 65:151-157.
-
(1999)
Am J Hum Genet
, vol.65
, pp. 151-157
-
-
Mangion, J.1
Rahman, N.2
Edkins, S.3
Barfoot, R.4
Nguyen, T.5
Sigurdsson, A.6
-
7
-
-
0034977079
-
Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism
-
Ueki Y., Tiziani V., Santanna C., Fukai N., Maulik C., Garfinkle J., et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001, 28:125-126.
-
(2001)
Nat Genet
, vol.28
, pp. 125-126
-
-
Ueki, Y.1
Tiziani, V.2
Santanna, C.3
Fukai, N.4
Maulik, C.5
Garfinkle, J.6
-
8
-
-
83255171065
-
Loss of tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism
-
Levaot N., Voytyuk O., Dimitriou I., Sircoulomb F., Chandrakumar A., Deckert M., et al. Loss of tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 2011, 147:1324-1339.
-
(2011)
Cell
, vol.147
, pp. 1324-1339
-
-
Levaot, N.1
Voytyuk, O.2
Dimitriou, I.3
Sircoulomb, F.4
Chandrakumar, A.5
Deckert, M.6
-
9
-
-
83255171058
-
Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease
-
Guettler S., LaRose J., Petsalaki E., Gish G., Scotter A., Pawson T., et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011, 147:1340-1354.
-
(2011)
Cell
, vol.147
, pp. 1340-1354
-
-
Guettler, S.1
LaRose, J.2
Petsalaki, E.3
Gish, G.4
Scotter, A.5
Pawson, T.6
-
10
-
-
12844271053
-
The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor
-
Foucault I., Le Bras S., Charvet C., Moon C., Altman A., Deckert M. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood 2005, 105:1106-1113.
-
(2005)
Blood
, vol.105
, pp. 1106-1113
-
-
Foucault, I.1
Le Bras, S.2
Charvet, C.3
Moon, C.4
Altman, A.5
Deckert, M.6
-
11
-
-
44149119302
-
SH3BP2 is an activator of NFAT activity and osteoclastogenesis
-
Lietman S.A., Yin L., Levine M.A. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun 2008, 371:644-648.
-
(2008)
Biochem Biophys Res Commun
, vol.371
, pp. 644-648
-
-
Lietman, S.A.1
Yin, L.2
Levine, M.A.3
-
12
-
-
33845988776
-
Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice
-
Ueki Y., Lin C.Y., Senoo M., Ebihara T., Agata N., Onji M., et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 2007, 128:71-83.
-
(2007)
Cell
, vol.128
, pp. 71-83
-
-
Ueki, Y.1
Lin, C.Y.2
Senoo, M.3
Ebihara, T.4
Agata, N.5
Onji, M.6
-
13
-
-
31044436261
-
M-CSF mediates TNF-induced inflammatory osteolysis
-
Kitaura H., Zhou P., Kim H.J., Novack D.V., Ross F.P., Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005, 115:3418-3427.
-
(2005)
J Clin Invest
, vol.115
, pp. 3418-3427
-
-
Kitaura, H.1
Zhou, P.2
Kim, H.J.3
Novack, D.V.4
Ross, F.P.5
Teitelbaum, S.L.6
-
14
-
-
84874445437
-
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
-
Burmester G.R., Panaccione R., Gordon K.B., McIlraith M.J., Lacerda A.P.M. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012, http://dx.doi.org/10.1136/annrheumdis-2011-201244.
-
(2012)
Ann Rheum Dis
-
-
Burmester, G.R.1
Panaccione, R.2
Gordon, K.B.3
McIlraith, M.J.4
Lacerda, A.P.M.5
-
15
-
-
78650990577
-
Pediatric rheumatology: JIA, treatment and possible risk of malignancies
-
Ruperto N., Martini A. Pediatric rheumatology: JIA, treatment and possible risk of malignancies. Nat Rev Rheum 2011, 7:6-7.
-
(2011)
Nat Rev Rheum
, vol.7
, pp. 6-7
-
-
Ruperto, N.1
Martini, A.2
-
16
-
-
84861363561
-
The role of SH3BP2 in the pathophysiology of cherubism
-
Reichenberger E.J., Levine M.A., Olsen B.R., Papadaki M.E., Lietman S.A. The role of SH3BP2 in the pathophysiology of cherubism. Orphanet J Rare Dis 2012, 7(Suppl. 1):S5.
-
(2012)
Orphanet J Rare Dis
, vol.7
, Issue.SUPPL. 1
-
-
Reichenberger, E.J.1
Levine, M.A.2
Olsen, B.R.3
Papadaki, M.E.4
Lietman, S.A.5
-
17
-
-
33846018444
-
Jawing about TNF: new hope for cherubism
-
Novack D.V., Faccio R. Jawing about TNF: new hope for cherubism. Cell 2007, 128:15-17.
-
(2007)
Cell
, vol.128
, pp. 15-17
-
-
Novack, D.V.1
Faccio, R.2
-
18
-
-
0031770934
-
Study of the cell biology and biochemistry of cherubism
-
Southgate J., Sarma U., Townend J.V., Barron J., Flanagan A.M. Study of the cell biology and biochemistry of cherubism. J Clin Pathol 1998, 51:831-837.
-
(1998)
J Clin Pathol
, vol.51
, pp. 831-837
-
-
Southgate, J.1
Sarma, U.2
Townend, J.V.3
Barron, J.4
Flanagan, A.M.5
-
19
-
-
0003713446
-
-
Sounders, Elsevier, Missouri, USA
-
Neville B., Damm D., Allen C., Bouquout J. Oral and maxillofacial pathology 2009, Sounders, Elsevier, Missouri, USA, pp. 629-630.
-
(2009)
Oral and maxillofacial pathology
, pp. 629-630
-
-
Neville, B.1
Damm, D.2
Allen, C.3
Bouquout, J.4
-
20
-
-
79955648483
-
Ineffectiveness of tumour necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism
-
Pagnini I., Simonini G., Mortilla M., Giani T., Pascoli L., Cimaz R. Ineffectiveness of tumour necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism. Clin Exp Rheumatol 2011, 29:147.
-
(2011)
Clin Exp Rheumatol
, vol.29
, pp. 147
-
-
Pagnini, I.1
Simonini, G.2
Mortilla, M.3
Giani, T.4
Pascoli, L.5
Cimaz, R.6
-
21
-
-
84861350007
-
Cherubism: best clinical practice
-
Papadaki M.E., Lietman S.A., Levine M.A., Olsen B.R., Kaban L.B., Reichenberger E.J. Cherubism: best clinical practice. Orphanet J Rare Dis 2012, 7(Suppl. 1):S6.
-
(2012)
Orphanet J Rare Dis
, vol.7
, Issue.SUPPL. 1
-
-
Papadaki, M.E.1
Lietman, S.A.2
Levine, M.A.3
Olsen, B.R.4
Kaban, L.B.5
Reichenberger, E.J.6
|